24 May 2013
Keywords: novartis, phase, iii, zelmac, data, treatment, irritable
Article | 27 October 1999
Novartis' treatment for irritable bowel syndrome Zelmac (tegaserod)has been shown to significantly reduce the key symptoms of IBS and
Enjoying this article? To continue reading you need to login or subscribe.
Subscriptions are £60 per month, pay as you go.
Find out more details.
28 October 1999
21 October 1999
23 May 2013
© 2013 thepharmaletter.com